Glycosmedia - an international diabetes news service from the UK
Archived News
March 19th 2010
  Navigating the Choices for Diabetes Prevention
  In this issue of the Journal, the investigators of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study report the results of their international trial (NEJM)
  ACCORD and Risk-Factor Control in Type 2 Diabetes
  The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study was one of the landmark trials to evaluate the overall effects of drug intervention in patients with type 2 diabetes (NEJM)
  ACCORD: Intensive BP treatment failed to reduce CV risk in patients with diabetes
  Intensive blood pressure treatment did not reduce the overall risk for cardiovascular events in patients with type 2 diabetes, elevated BP and high CV risk when compared with more conventional therapy, according to new data from the ACCORD Blood Pressure trial (Cardiology Today)
  Commencement of the Saxagliptin Assessment of Vascular Outcomes
  Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (PharmaLive)
  Generic Drug for Type 2 Diabetes Passes Next Clinical Hurdle
  Salsalate, an anti-inflammatory agent, shows encouraging results in preliminary trial led by (Joslin Diabetes Center)
  FDA turns down once-weekly Byetta
  Amylin, Eli Lilly and Alkermes will have to wait a bit longer before they can start selling a once-weekly version of its diabetes blockbuster Byetta as regulators in the USA want clarification on the labelling (PharmaTimes)
  Endothelial Dysfunction: the Common Consequence in Diabetes and Hypertension
  Endothelial dysfunction plays a key role in the initiation of cellular events evolving into the development of vascular complications in diabetes and hypertension - Abstract (Journal of Cardiovascular Pharmacology)
  Testosterone concentrations in diabetic and non-diabetic obese men
  40% of obese non-diabetic and 50% of obese diabetic men above the age of 45 years have subnormal FT concentrations (Diabetes Care)
  IDF appoints Special Ambassador for the Rights of People with Diabetes
  The International Diabetes Federation (IDF) is pleased to announce the appointment of Dr Wim Wientjens as IDF Special Ambassador for the Rights of People with Diabetes (IDF)
  Primary Care Diabetes
  April edition (PCD)
© Copyright Glycosmedia Partnership